Long-term Follow-up Study of GLPG0634 in Active Rheumatoid Arthritis Patients
Active, not recruiting
Gilead Sciences
Phase 2
The primary objective of the study is to evaluate the long-term safety and tolerability of
filgotinib (formerly GLPG0634) for the treatment of rheumatoid arthritis.
Participants will be enrolled in this open-label long-term follow-up study after they have
completed one of the two core studies, GLPG0634-CL-203 (DARWIN1) or GLPG0634-CL-204
(DARWIN2), and will be evaluated for any side effects that may occur (long-term safety and
tolerability) when taking filgotinib. During the course of the study, participants will also
be examined for long-term effects of filgotinib administration on disease activity
(efficacy), subjects' disability, fatigue, and quality of life.
Long-term Follow-up Study of GLPG0634 in Active Rheumatoid Arthritis Patients
Active, not recruiting
Galapagos NV
Phase 2
The primary objective of the study is to evaluate the long-term safety and tolerability of
filgotinib (formerly GLPG0634) for the treatment of rheumatoid arthritis.
Participants will be enrolled in this open-label long-term follow-up study after they have
completed one of the two core studies, GLPG0634-CL-203 (DARWIN1) or GLPG0634-CL-204
(DARWIN2), and will be evaluated for any side effects that may occur (long-term safety and
tolerability) when taking filgotinib. During the course of the study, participants will also
be examined for long-term effects of filgotinib administration on disease activity
(efficacy), subjects' disability, fatigue, and quality of life.
Filgotinib Versus Placebo in Adults With Active Rheumatoid Arthritis (RA) Who Have an Inadequate Response to Biologic Disease-modifying Anti-rheumatic Drug(s) (DMARDs) Treatment
Completed
Galapagos NV
Phase 3
The primary objective of this study is to evaluate the effects of filgotinib versus placebo
for the treatment of signs and symptoms of rheumatoid arthritis (RA) as measured by the
percentage of participants achieving an American College of Rheumatology 20% improvement
response (ACR20) at Week 12.
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models.
By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.
